2-methyl-4-(3-nitrobenzylidene)oxazol-5(4H)-one | 57731-07-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-methyl-4-(3-nitrobenzylidene)oxazol-5(4H)-one
• 英文别名: 2-methyl-4-(3-nitrobenzylidene)-2-methyloxazol-5(4H)-one；5(4H)-Oxazolone, 2-methyl-4-[(3-nitrophenyl)methylene]-；2-methyl-4-[(3-nitrophenyl)methylidene]-1,3-oxazol-5-one
• CAS: 57731-07-4
• 化学式: C₁₁H₈N₂O₄
• 分子量: 232.196
• InChiKey: ABNNCLKVUMXLSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  84.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-methyl-4-(3-nitrobenzylidene)oxazol-5(4H)-one 在 盐酸 、 水 、 sodium ethanolate 作用下， 以 甲醇 为溶剂， 反应 6.5h， 生成 2-hydroxy-3-(3-nitrophenyl)propionic acid
  参考文献：
  名称：

  COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD

  摘要：

  公开号：

  EP1910270B3
• 作为产物：
  描述：

  间硝基苯甲醛 、 N-乙酰甘氨酸 在 sodium acetate 、 乙酸酐 作用下， 反应 8.0h， 生成 2-methyl-4-(3-nitrobenzylidene)oxazol-5(4H)-one
  参考文献：
  名称：

  机械引导的一锅法合成膦-亚磷酸酯及其在不对称加氢中的意义

  摘要：

  杂化磷配体的合成是一项多步骤、耗时的工作。通过对杂化配体形成过程的细致了解，这一限制得到了解决，并且首次报道了膦-亚磷酸酯配体 (L1) 的一锅合成。L1 与 Rh 配位并催化 15 种底物的不对称氢化，具有 2289 的高 TOF 和 92% 的对映体过量。

  DOI：

  10.1002/ejoc.202101447

文献信息

• Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field
  申请人：Naccari Giancarlo

  公开号：US20090048343A1

  公开（公告）日：2009-02-19

  The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

  本发明涉及具有一般式（I）的化合物，其中R1和R2，可以相同也可以不同，选自包括-H或具有1至6个碳原子的直链或支链烷基基团，或者共同形成具有5或6个原子的芳香或脂肪环的群；Y和Z，可以相同也可以不同，选自包括-H，-OH，-COOH，-OR3，-CH(OR3)COOH的群，其中R3选自H，苯基，苄基，-CF3或-CF2 ，乙烯基，烯丙基和具有1至6个碳原子的直链或支链烷基基团。
• Synthesis, In Silico Prediction and In Vitro Evaluation of Antimicrobial Activity, DFT Calculation and Theoretical Investigation of Novel Xanthines and Uracil Containing Imidazolone Derivatives
  作者：Samar El-Kalyoubi、Fatimah Agili、Wael A. Zordok、Ashraf S. A. El-Sayed

  DOI：10.3390/ijms222010979

  日期：——

  oxazolones 2a-c in presence of drops of acetic acid under fused condition yielding the imidazolone derivatives 6-13. Furthermore, Schiff base of compounds 14-16 were obtained by condensing 5, 6-diaminouracils 1a,b,e with 4-dimethylaminobenzaldehyde in acetic acid. The structural identity of the resulting compounds was resolved by IR, 1H-, 13C-NMR and Mass spectral analyses. The novel synthesized compounds

  以恶唑酮衍生物2a-c为关键中间体，合成了新型黄嘌呤和咪唑酮衍生物。恶唑酮衍生物2a-c与5,6-二氨基尿嘧啶1a-e在不同条件下反应得到相应的黄嘌呤3-5和咪唑酮衍生物6-13 。黄嘌呤化合物3-5是通过5,6-二氨基尿嘧啶1a-c与不同恶唑酮在冰醋酸中环缩合得到的。此外，5, 6-二氨基尿嘧啶1a-e与恶唑酮2a-c在乙酸滴的存在下在熔融条件下反应，产生咪唑酮衍生物6-13 。此外，通过将5, 6-二氨基尿嘧啶1a,b,e与4-二甲氨基苯甲醛在乙酸中缩合，得到化合物14-16的席夫碱。通过IR、 1 H-、 13 C-NMR 和质谱分析解析所得化合物的结构特性。筛选了新合成的化合物的抗真菌和抗菌活性。从 IC 50值 ( 1.8–1.9 µg/mL)可以看出，化合物3、6、13和16对大肠杆菌表现出最高的活性。与真正的抗生素相比，化合物16对白色念珠菌(0.82 µg/mL)、黄曲霉(1
• New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
  作者：Matthias G. J. Baud、Thomas Leiser、Franz-Josef Meyer-Almes、Matthew J. Fuchter

  DOI：10.1039/c0ob00824a

  日期：——

  New synthetic routes towards the natural product psammaplin A were developed with the particular view to preparing diverse analogues for biological assessment. These routes utilize cheap and commercially available starting materials, and allowed access to psammaplin A analogues not accessible via currently reported methods. Preliminary biological studies revealed these compounds to be the most potent non peptidic inhibitors of the enzyme histone deacetylase 1 (HDAC1, class I) discovered so far. Interestingly, psammaplin A and our synthetic analogues show class I selectivity in vitro, an important feature for the design and synthesis of future isoform selective inhibitors.

  开发了新的合成路线以制备天然产物海绵抑素A（psammaplin A）及其多样化的类似物，这些类似物用于生物学评估。这些路线采用廉价且商业可获得的起始原料，并能合成目前报道方法难以获得的psammaplin A类似物。初步生物学研究表明，这些化合物是目前所发现的最强效的非肽类组蛋白去乙酰化酶1（HDAC1，I类）抑制剂。有趣的是，psammaplin A及其我们的合成类似物在体外显示出I类选择性，这对于设计和合成未来同工型选择性抑制剂具有重要意义。
• Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
  申请人：Giuliani International Limited

  公开号：US08153841B2

  公开（公告）日：2012-04-10

  The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

  本发明涉及具有通式（I）的化合物，其中R1和R2可能相同或不同，选自包括-H或具有1至6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体; Y和Z可能相同或不同，选自包括-H，-OH，-COOH，-OR3，-CH（OR3）COOH，其中R3选自H，苯基，苄基，-CF3或-CF2 ，乙烯基，丙烯基和具有1至6个碳原子的线性或支链烷基。
• Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field
  申请人：Naccari Giancarlo

  公开号：US20130005813A1

  公开（公告）日：2013-01-03

  The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

  本发明涉及通式（I）的化合物，其中R1和R2可以相同或不同，选自包括-H或具有1到6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体；Y和Z可以相同或不同，选自包括-H、-OH、-COOH、-OR3、-CH（OR3）COOH的群体，其中R3选自H、苯基、苄基、-CF3或-CF2 、乙烯基、丙烯基和具有1到6个碳原子的线性或支链烷基。